Francesca Casaluce,Assunta Sgambato,Paolo Maione et al.
Francesca Casaluce et al.
KRAS is the most frequently mutated oncogene in NSCLC, occurring in around a third of patients. However, this largest genomically defined subgroup of lung cancer patients seem to remain 'undruggable', with any effective targeted therapy app...
Vipul Jairath,Reena Khanna,Brian G Feagan
Vipul Jairath
Intracellular adhesion molecule-1 (ICAM-1), is a transmembrane glycoprotein of the immunoglobulin family, constitutively expressed on vascular endothelial cells and upregulated in inflamed colonic tissue. Alicaforsen, a 20 base ICAM-1 anti-...
Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives [0.03%]
布鲁顿酪氨酸激酶抑制剂在B细胞淋巴瘤中的应用：目前进展与未来展望
T Seiler,M Dreyling
T Seiler
The Bruton tyrosine kinase (BTK) is a central hub in the B cell receptor (BCR) pathway and strongly influences B cell maturation, differentiation and proliferation. Not surprisingly, BTK plays an essential role in the pathogenesis of variou...
A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects [0.03%]
一项在健康受试者中评估BI 695502（贝伐珠单抗类似药）生物等效性和安全性的随机、单盲I期试验（INVICTAN-1）
Willem Hettema,Christopher Wynne,Benjamin Lang et al.
Willem Hettema et al.
Objectives: This Phase I trial (INVICTAN®-1) evaluated three-way bioequivalence and safety of BI 695502 a bevacizumab biosimilar candidate, and reference product bevacizumab from two sources (US-approved Avastin®, Genen...
Christos C Zouboulis,Clio Dessinioti,Fragkiski Tsatsou et al.
Christos C Zouboulis et al.
Despite the impressive increase of knowledge on acne etiology accumulated during the last 20 years, few efforts have been overtaken to introduce new therapeutic regiments targeting the ideal treatment of acne. The increasing emergence of mi...
Drugs currently under investigation for the treatment of invasive candidiasis [0.03%]
目前用于治疗侵袭性念珠菌病的药物 исследование
Matthew W McCarthy,Thomas J Walsh
Matthew W McCarthy
The widespread implementation of immunosuppressants, immunomodulators, hematopoietic stem cell transplantation and solid organ transplantation in clinical practice has led to an expanding population of patients who are at risk for invasive ...
Kalliopi Pafili,Efstratios Maltezos,Nikolaos Papanas
Kalliopi Pafili
In 2017, the management of type 1 diabetes mellitus (T1DM) remains intriguing for the clinician, who has to balance between adequate glycemic control and untoward events related to insulin up-titration. Thus, agents that will complement ins...
Nicola Conran,David C Rees
Nicola Conran
Therapeutic options for sickle cell disease (SCD) are limited and, currently, only one drug (hydroxyurea) has FDA approval for the treatment of adult SCD. While this genetic disease is caused by hemoglobin polymerization, subsequent downstr...
Developments with experimental and investigational drugs for axial spondyloarthritis [0.03%]
轴型脊柱关节炎的试验性和探究性药物进展
Gaëlle Clavel,Marie-Christophe Boissier,Johanna Sigaux et al.
Gaëlle Clavel et al.
Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from ...
Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk [0.03%]
敌人还是武器：抗糖尿病药物格列本脲与癌症风险研究
Rui Gao,Tao Yang,Wei Xu
Rui Gao
Epidemiological evidence suggests that diabetes is associated with elevated cancer risk through the actions of hyperglycemia, hyperinsulinemia and chronic inflammation. Metformin, a first-line medication for type 2 diabetes mellitus, arouse...